Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Jun 27, 2024 4:12pm
81 Views
Post# 36109602

RE:RE:It Was Just A Typo

RE:RE:It Was Just A Typo"if it was he who responded"

tim mccarthy is on the corporate website as the IR contact with his phone number listed.  tim didn't "respond", i called him at the listed number, he answered the phone, and he said it was a typo.

just got this response from jon patton:


Jon Patton
From:jpatton@oncolytics.ca
To:Dave 
Thu, Jun 27 at 4:03 PM
 

Hi Dave,

 

This is an inadvertent holdover from a previous S-8 and utterly inconsequential. Dr. Thompson holds no rights, authority or power of attorney in relation to Oncolytics Biotech nor does he have any involvement with the company. We have confirmed with US counsel that no action is required, and we consider this matter closed.

 

Best,

Jon

 

Confidentiality Notice: This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. Any other distribution, copying or disclosure is strictly prohibited. If you have received this message in error, please notify the sender immediately by return e-mail or by telephone at (403-670-7377) (Canada) and electronically delete this message without making a copy.

 


and this is response from counsel this morning:

Bennett, Michael J.
 
From:
mbennett@mccarthy.ca
To:
Dave 
 
Thu, Jun 27 at 9:34 AM
 
Entirely understandable that you may have formed that view; however, our opinion which we were required to provide in connection with the filing of the Form S-8 with the SEC does not speak to the Form S-8 filing in any way, including as to its accuracy or completeness.  Rather, our opinion relates solely to the status of the common shares issuable upon exercise of options and vesting of restricted share awards and fully-paid and non-assessable shares of the company under and in accordance with Alberta corporate law.  It is not  necessary for us to review the Form S-8 in order to render an opinion to that effect.
 
 
 
From: Dave 
Sent: Wednesday, June 26, 2024 9:02 PM
To: Bennett, Michael J. <MBENNETT@mccarthy.ca>
Subject: Re: [EXT] Fw: oncolytics biotech
 
 
 
Mr. Bennett,
 
 
 
Thank you for your reponse.  However, as noted in the information below, your firm provided the consent and opinion in connection with the preparation and filing with the United States SEC under the United States Securities Act of 1933, as amended, of Oncolytics Registration Statement on Form S-8.
 
 
 
That is one of the reasons I was reaching out to your firm for an explanation regarding the appointment of Brad Thompson as the attorney-in-fact for the 9 officers and directors of Oncolytics who signed the document.
 
 
 
Since your firm examined all of the records, documents, agreements etc. associated with the Registration Statement, it seemed that you would be in a position to comment.


<< Previous
Bullboard Posts
Next >>